RNA therapeutics are a new class of medicines with broad applicability against disease-relevant proteins. Proteins are large, complex molecules that play a critical role in the body's capacity to stay healthy. Most approved drugs today are small molecules or protein biologics, which can only reach a limited number of proteins or genes. Our RNA-based therapeutics are designed to selectively trigger a patient's own cells to produce therapeutic proteins where they are needed most.
ValamAi is building a differentiated pipeline of first-in-class RNA medicines, powered by a proprietary mRNA technology platform, with the goal of bringing new options to patients with limited treatment alternatives.
Learn about our technology ›